Why Is Novo Nordisk Buying a Rare-Disease Candidate?

·4-min read

Novo Nordisk (NYSE: NVO) recently announced that it's buying Prothena's (NASDAQ: PRTA) transthetyrin amyloidosis (ATTR) cardiomyopathy program for up to $1.2 billion. In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Novo, which is best known for its diabetes franchise, is buying a rare-disease drug candidate. There is a company, I don't know that we've talked about much, if at all in the past, Brian, Novo Nordisk.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting